好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Exploring the Influence of Social Drivers of Health on Ambulatory Capacity in Stiff Person Syndrome Spectrum Disorders
Autoimmune Neurology
P4 - Poster Session 4 (8:00 AM-9:00 AM)
2-002

To determine if social drivers of health (SDoH) are associated with ambulatory capacity in people with stiff person syndrome spectrum disorders (SPSD).

While SDoH have been linked to worse outcomes in other autoimmune neurological disorders like multiple sclerosis and myasthenia gravis, their impact on SPSD remains unexplored.

As part of an ongoing longitudinal observational study at a tertiary care center, data were systematically collected. We used multivariate logistic regression to examine relationships between SDoH and ambulatory capacity in people with SPSD, controlling for age at symptom onset and SPS phenotype (classic SPS, SPS plus, partial SPS, and Progressive Encephalomyelitis with Rigidity and Myoclonus). We report odds ratios (OR) for having more severe ambulatory impairment, their 95% confidence intervals (CIs), and p-values.

We included 230 people with SPSD; 41.74% required ambulatory assistance. Non-white identity (OR 2.23, 95% CI 1.22-3.73, p = 0.008) and prior heavy alcohol use (OR 15.89, 95% CI 2.56-98.63, p = 0.003) were associated with greater odds of ambulatory impairment, while male sex (OR 0.35, 95% CI 0.18-0.68, p = 0.002) appeared protective. Marital status, educational attainment, tobacco use, and illicit drug use were not significantly associated with ambulatory status in our cohort.

As in other autoimmune neurologic conditions, outcomes in SPSD may be influenced by SDoH. In our cohort, non-white individuals and those with a history of heavy alcohol use had  increased  odds of ambulatory impairment, while male individuals had reduced odds. These associations warrant further investigation to better understand underlying mechanisms and inform equitable care strategies.

Authors/Disclosures
Alexandra R. Balshi
PRESENTER
Ms. Balshi has nothing to disclose.
Barrett Crawford Mr. Crawford has nothing to disclose.
Hanyeh Afshar Ms. Afshar has nothing to disclose.
Sarah Snoops, RN Mrs. Snoops has nothing to disclose.
Scott D. Newsome, DO, FAAN (Johns Hopkins Hospital) Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Newsome has received research support from Biogen. The institution of Dr. Newsome has received research support from Genentech/Roche. The institution of Dr. Newsome has received research support from Department of Defense. The institution of Dr. Newsome has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Newsome has received research support from National MS Society. The institution of Dr. Newsome has received research support from Lundbeck. The institution of Dr. Newsome has received research support from Sanofi. The institution of Dr. Newsome has received research support from Kyverna Therapeutics. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving as a Lead PI for Clinical Trial with Roche.